| pubmed-article:14504921 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14504921 | lifeskim:mentions | umls-concept:C0023980 | lld:lifeskim |
| pubmed-article:14504921 | lifeskim:mentions | umls-concept:C0439849 | lld:lifeskim |
| pubmed-article:14504921 | lifeskim:mentions | umls-concept:C0237865 | lld:lifeskim |
| pubmed-article:14504921 | lifeskim:mentions | umls-concept:C1704241 | lld:lifeskim |
| pubmed-article:14504921 | lifeskim:mentions | umls-concept:C1705241 | lld:lifeskim |
| pubmed-article:14504921 | lifeskim:mentions | umls-concept:C1705242 | lld:lifeskim |
| pubmed-article:14504921 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:14504921 | pubmed:dateCreated | 2003-12-23 | lld:pubmed |
| pubmed-article:14504921 | pubmed:abstractText | DNA topoisomerase II (topo II) is an important cellular target for chemotherapeutic agents. Human cells have two isoforms of topo II (alpha and beta), and both are inhibited by the chemotherapeutic agents etoposide, amsacrine (mAMSA) and mitoxantrone. It is known that the cytotoxic importance of topo IIalpha or topo IIbeta drug-induced complexes differs depending on which drug is present. This study was designed to (a) assess isoform-specific formation and reversal of topo IIalpha and beta cleavable complexes, and (b) determine whether the cytotoxic importance of either isoform was related to differences in the longevity of the complexes. | lld:pubmed |
| pubmed-article:14504921 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14504921 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14504921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14504921 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14504921 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:14504921 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:14504921 | pubmed:author | pubmed-author:AustinCarolin... | lld:pubmed |
| pubmed-article:14504921 | pubmed:author | pubmed-author:WillmoreElain... | lld:pubmed |
| pubmed-article:14504921 | pubmed:author | pubmed-author:ErringtonFion... | lld:pubmed |
| pubmed-article:14504921 | pubmed:author | pubmed-author:TilbyMichael... | lld:pubmed |
| pubmed-article:14504921 | pubmed:author | pubmed-author:LeontiouChrys... | lld:pubmed |
| pubmed-article:14504921 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14504921 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:14504921 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14504921 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14504921 | pubmed:pagination | 155-62 | lld:pubmed |
| pubmed-article:14504921 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:meshHeading | pubmed-meshheading:14504921... | lld:pubmed |
| pubmed-article:14504921 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:14504921 | pubmed:articleTitle | Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity. | lld:pubmed |
| pubmed-article:14504921 | pubmed:affiliation | School of Cell and Molecular BioSciences, The Medical School, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, NE2 4HH, UK. | lld:pubmed |
| pubmed-article:14504921 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14504921 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14504921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14504921 | lld:pubmed |
